Drugmaker AstraZeneca lifted its annual sales and profit forecast for the second time this year on Tuesday, helped by strong ...

AstraZeneca has become the latest big pharma company to devote new cash to its US manufacturing muscle this year as it ...

AstraZeneca's China president Leon Wang, who was detained last month by Chinese authorities, is in touch with a lawyer but ...

AstraZeneca Plc is increasingly looking to the US for growth as its once fast-expanding China business faces challenges amid ...

AstraZeneca said it plans to pump $2 billion in new investment into the U.S., one of the first major foreign companies to ...

Bernstein analyst Justin Smith maintained a Buy rating on AstraZeneca (AZN – Research Report) today and set a price target of p18,000.00. Justin Smith has given his Buy rating due to a combination of ...

In closing its therapeutics division and laying off 200 people, 23andMe ended an audacious bet it made nearly a decade ago — ...

Cambridge, England-based biopharmaceutical giant AstraZeneca is pouring billions of dollars into properties in the United ...

Drugmaker AstraZeneca lifted its annual sales and profit forecast for the second time in less than four months on Tuesday, ...

AstraZeneca PLC aims for $80 billion revenue by 2030 through strong growth in oncology, biopharmaceuticals, and rare diseases ...

AstraZeneca’s earnings were boosted by its oncology, cardiovascular, respiratory and immunology (R&I), and rare disease ...

Eric Le Berrigaud, an analyst from Stifel Nicolaus, reiterated the Buy rating on AstraZeneca (AZN – Research Report). The associated price target remains the same with p14,100.00. Eric Le Berrigaud ...